EU Joint Clinical Assessments (JCA)
Supporting pharmaceutical companies from early evidence strategy through EU JCA submission, assessment, and national market access in Europe
Navigate EU Joint Clinical Assessment with Confidence
The EU Joint Clinical Assessment (EU JCA) is transforming how sponsors prepare evidence for European market access. A coordinated EU-level clinical assessment now runs alongside regulatory review, while pricing, reimbursement, and important elements of HTA decision-making remain national.
This creates a new challenge: evidence must be planned early enough to support European assessment while remaining relevant to the national decisions that follow. Success requires more than dossier preparation; it demands early evidence planning, methodological rigor, statistical expertise, and alignment between global and local market access strategies.
Cytel helps sponsors navigate the full journey: from early evidence strategy and PICO simulation through advanced analytics, JCA dossier development, post-submission support, and national HTA implementation.
Talk to an EU JCA expertWhy EU JCA is Different
EU JCA changes much more than the submission format. Multiple Member States contribute to the scoping process, potentially creating numerous PICO questions across different populations, comparators, and outcomes. The resulting evidence requirements can create substantial analytical complexity, particularly where the clinical development program does not contain direct evidence for every relevant comparison.
At the same time, the formal preparation timeline is compressed. Sponsors therefore cannot wait for the final JCA scope before determining whether the necessary evidence exists.
Successful preparation begins earlier — through PICO simulation, evidence mapping, systematic literature review, comparative-effectiveness, feasibility assessment and alignment between clinical, regulatory, and market access teams.
| Traditional HTA | EU JCA |
| Country specific | One coordinated EU assessment |
| Local evidence | Multiple Member State PICOs |
| National timelines | Parallel with EMA |
| Individual submissions | One evidence package supporting 27 countries |
EU JCA is one step in the market access journey – not the destination.
We help you succeed at every step.
Talk to an EU JCA expert
An Integrated Evidence Strategy
Cytel approaches EU JCA as an evidence challenge rather than simply a dossier requirement. Our Market Access experts work alongside evidence synthesis, comparative effectiveness, biostatistics, RWE, medical writing, and local HTA specialists to build one connected evidence strategy. That cross-functional model enables us to identify risks earlier, select the appropriate analytical approach, and maintain consistency between evidence generation, JCA submission, and subsequent national HTA.
First-Wave Experience. Ongoing Learning.
The first wave of EU JCA has reinforced how much practical implementation can differ from simply reading regulatory guidance. PICO complexity, evidence gaps, methodological justification, compressed timelines, and the interaction between JCA and national HTA all require judgement as well as technical knowledge.
Cytel combines direct JCA delivery experience with methodological publications, thought leadership, and deep national HTA expertise. This allows our teams to apply both the written guidance and the practical lessons emerging from real assessments.
300+
Oncology publications in the last 5 years
300+
Systematic literature reviews
280+
Comparative effectiveness analyses
40+
Markets supported worldwide
Why Choose Cytel?
Scientific Expertise
Experts in HTA, statistics, evidence synthesis, comparative effectiveness and market access working as one integrated team (link to EVA)
Integrated Delivery
Evidence generation, advanced analytics, dossier development and local HTA support delivered through one coordinated program
Real-world Experience
Supporting first-wave EU JCA programs from strategy through submission and post-submission activities
Beyond the Dossier
Helping sponsors translate EU JCA outcomes into successful national market access strategies
FAQ - EU JCA
What is an EU Joint Clinical Assessment?
An EU JCA is a coordinated assessment of the relative clinical effectiveness and safety of certain health technologies under the EU HTA Regulation. It provides a common European clinical assessment that Member States can use in their national HTA processes.
Does EU JCA replace national HTA?
No. EU JCA addresses the joint clinical assessment, while pricing, reimbursement, economic evaluation and other country-specific considerations remain national responsibilities.
When should companies start preparing for EU JCA?
Preparation should begin well before the formal JCA process starts. Potential PICOs, comparator evidence, analytical feasibility and evidence gaps may need to influence clinical development and evidence-generation decisions months or years before submission.
Which medicines currently undergo EU JCA?
The phased implementation began with oncology medicines and ATMPs in 2025. Orphan medicinal products enter scope from 2028, followed by all centrally authorized medicines from 2030.
Why is PICO simulation important?
PICO simulation helps sponsors anticipate potential populations, interventions, comparators and outcomes that Member States may request. Although it cannot perfectly predict the final scope, it can identify evidence risks early enough to support planning.
Our Resources
Webinar – Navigating the First Year of EU JCA Implementation: Updates, Methodological Insights, and Bridging Local HTA Realities
e-book – Navigating EU JCA: Submissions and Local HTA Decision-Making
Webinar – Real-World Evidence in the Era of EU JCA: How to Target Several Countries with a Single Protocol
We help sponsors prepare for JCAs
Preparing for an upcoming EU JCA? Talk to Cytel’s experts about building an integrated evidence strategy.